All In Biotech

Drug Trial Radar · NCT00504881

Brivaracetam as add-on Treatment in Adolescents and Adults Suffering From Epilepsy

An International, Randomized, Double-blind, Parallel-group, Placebo-controlled, Flexible Dose Study: Evaluation of the Safety and Efficacy of Brivaracetam in Subjects (≥ 16 to 70 Years Old) Suffering From Localization-related or Generalized Epilepsy.

Last checked: Nov 20, 2026Latest source record: Apr 3, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 480 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

480

Actual

Start

Oct 2007

Primary completion

Nov 2008

Study completion Dec 2008

Sponsor

Lead sponsor
UCB Pharma SAUCB
Sponsor type
Industry
First posted
Jul 20, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 16 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will compare the safety and efficacy of Brivaracetam at flexible dose with Placebo in subjects suffering from Epilepsy.

Conditions

  • Epilepsy

Interventions

  • PlaceboDrug

    Daily oral dose of two equal intakes, morning and evening, of Placebo in a double-blinded way for the 16-week Treatment Period

  • BrivaracetamDrug

    Daily oral dose of two equal intakes, morning and evening, Brivaracetam 20 mg/day or Brivaracetam 50 mg/day or Brivaracetam 100 mg/day or Brivaracetam 150 mg/day, in a double-blinded way for the 16-week Treatment Period

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Subjects With at Least One Adverse Event During the 16-week Treatment PeriodTime frame: Week 2 to the end of the Treatment Period (Week 16)
  2. Partial Onset Seizure (Type I) Frequency Per Week Over the 16-week Treatment PeriodTime frame: Baseline (Week 0) to the end of the Treatment Period (Week 16)

Locations

61 sites in 15 countries. Site status is shown where the registry gives one.

  • Site not named

    Graz, Austria

  • Site not named

    Innsbrick, Austria

  • Site not named

    Linz, Austria

  • Site not named

    Vienna, Austria

  • Site not named

    Bruges, Belgium

  • Site not named

    Godinne, Belgium

  • Site not named

    Leuven, Belgium

  • Site not named

    Montignies-sur-Sambre, Belgium

  • Site not named

    Beroun, Czechia

  • Site not named

    Brno, Czechia

  • Site not named

    Ostrava Trebovice, Czechia

  • Site not named

    Prague, Czechia

  • Site not named

    Zlín, Czechia

  • Site not named

    Berlin, Germany

  • Site not named

    Bernau, Germany

  • Site not named

    Bielefeld, Germany

  • Site not named

    Erlangen, Germany

  • Site not named

    Göttingen, Germany

  • Site not named

    Jena, Germany

  • Site not named

    München, Germany

  • Site not named

    Hong Kong, Hong Kong

  • Site not named

    Bangalore, India

  • Site not named

    Hyderabad, India

  • Site not named

    Mumbai, India

  • Site not named

    New Delhi, India

  • Site not named

    Pune Maharashtra, India

  • Site not named

    Tirupati, India

  • Site not named

    Bari, Italy

  • Site not named

    Milan, Italy

  • Site not named

    Pavia, Italy

  • Site not named

    Roma, Italy

  • Site not named

    Siena, Italy

  • Site not named

    Bergen, Norway

  • Site not named

    Fredrikstad, Norway

  • Site not named

    Oslo, Norway

  • Site not named

    Sandvika, Norway

  • Site not named

    Trondheim, Norway

  • Site not named

    Kazan', Russia

  • Site not named

    Moscow, Russia

  • Site not named

    Saint Petersburg, Russia

Showing 40 of 61 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.